Atriva Therapeutics
Therapies against viral infections.
The Atriva Approach
First-in-class host-targeting therapies to treat respiratory viral infections, including COVID-19 and influenza.
Great potential against a wide variety of respiratory viruses due to immunomodulating and antiviral activity of ATRIVA’s lead product zapnometinib (INN). Phase I clinical trial successfully completed, RESPIRE (a Phase II clinical trial in COVID-19) started patient enrollment in April 2021. A Phase II study in influenza is currently planned.
Atriva News
Stay informed on Atriva Therapeutics
Atriva Therapeutics receives U.S. FDA Orphan Drug Designation for Zapnometinib to treat Hantavirus Infections
Atriva Therapeutics to take part in upcoming scientific and industry conferences
Atriva Therapeutics to take part in upcoming scientific and industry conferences in early 2022
Atriva Therapeutics to take part in upcoming scientific and industry conferences
Atriva Therapeutics strengthens advisory board with Piet Wigerinck
Atriva Therapeutics to take part in upcoming scientific and industry conferences
Atriva Therapeutics’ lead candidate Zapnometinib shows substantial efficacy against SARS-CoV-2
Atriva Therapeutics to take part in upcoming scientific and industry conferences
Spahn/Karliczek: Weiterer Schub zur Entwicklung und Herstellung von versorgungsnahen Arzneimitteln gegen COVID-19
Förderung von Arzneimittelkandidaten gegen COVID-19 aus der Fördermaßnahme „Klinische Entwicklung von versorgungsnahen COVID-19-Arzneimitteln und deren Herstellungskapazitäten“ von BMG und BMBF.
Atriva Therapeutics to take part in upcoming scientific and industry conferences
Atriva Therapeutics to take part in upcoming scientific and industry conferences
Atriva Therapeutics kann dank Fördermitteln COVID-19-Medikament schneller entwickeln
Das biopharmazeutische Unternehmen Atriva Therapeutics GmbH, ein Vorreiter bei der Entwicklung von Therapien zur Behandlung von viralen Infektionen, hat sich Fördermittel des …
Atriva Therapeutics to Speed up Development of COVID-19 Drug with Federal Funding
Atriva Therapeutics GmbH, a company that is pioneering the development of therapies for the treatment of viral infections, has secured up to …
Atriva Therapeutics Doses First Patient in Phase II RESPIRE trial in COVID-19
Atriva Therapeutics GmbH, a biopharmaceutical company that is pioneering the development of host-targeting antiviral therapies, announced today that the first patient was …
Atriva Therapeutics Announces Changes to Management in COVID-19
Atriva Therapeutics GmbH, a biopharmaceutical company that is pioneering the development of host-targeting antiviral therapies, today announced two changes to its management …